<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01586715</url>
  </required_header>
  <id_info>
    <org_study_id>HULPCIR-2010-01</org_study_id>
    <secondary_id>2010-024329-19</secondary_id>
    <nct_id>NCT01586715</nct_id>
  </id_info>
  <brief_title>Stem Cells Treatment for Extremely Complex Fistulae (HULPCIR)</brief_title>
  <official_title>A Phase IIa Clinical Trial to Study the Treatment of the Extremely Complex and Conventional Treatment Resistant Perianal Fistulae With Autologous Stem Cells From Lipoaspirate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto de Investigación Hospital Universitario La Paz</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto de Investigación Hospital Universitario La Paz</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the practicability of the autologous e-ASC
      (Autologous Stem Cells) for the treatment of extremely complex and treatment resistant
      perianal fistulae.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">December 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of treatment of extremely complex perianal fistulae. Percentage of treated extremely complex perianal fistulae and percentage of subjects with closed fistulae</measure>
    <time_frame>16 weeks</time_frame>
    <description>Safety by control the adverse effects associated with treatment Fistula close by 3D ultrasound</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life assessment using the SF-12 Questionnaire</measure>
    <time_frame>1, 4, 16,24 weeks</time_frame>
    <description>Test SF-12 of quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>1, 4, 12, 24 weeks</time_frame>
    <description>Control by investigation team of CRD (data collections)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Extremely Complex Perianal Fistulae</condition>
  <arm_group>
    <arm_group_label>Autologous Stem Cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adipose-derived stem cells without expanded</intervention_name>
    <description>Administration will be intralesional injection of cells suspension. They will be placed into fistula walls</description>
    <arm_group_label>Autologous Stem Cells</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent

          -  Extremely Complex perianal fistulae

          -  Men and women over 18 years old. Good general state of health according to the
             findings of the clinical history and the physical examination

          -  Previous failure in at least one closing fistula standard treatment

        Exclusion Criteria:

          -  Presence of severe proctitis or dominant active luminal disease requiring immediate
             therapy

          -  Patients with an abscess unless a complete toilet of the area with drainage of the
             collections and the absence of abscess and other collections is confirmed prior to
             treatment start

          -  Patients with a history of abuse of alcohol or other addictive substances in the 6
             months prior to inclusion

          -  Patients with malignant tumor, except for basal cell or cutaneous squamous cell
             carcinoma, or patients with a prior history of malignant tumors, unless the neoplastic
             disease has been in remission for the previous 5 years

          -  Patients with cardiopulmonary disease which, in opinion of the investigator, in
             unstable or sufficiently serious to exclude the patient from the study.

          -  Patients with any type of medical or psychiatric disease which, in the opinion of the
             investigator, could be grounds for exclusion from study

          -  Patients with congenital or acquired immunodeficiencies. HIV, HBV, HCV or treponema
             infection, whether active or latent

          -  Patients who have suffering major surgery or severe trauma in the prior 6 months

          -  Pregnant or breastfeeding women

          -  Patients currently receiving, or having received within 1 month prior to enrollment
             into this clinical trial, any investigational drug
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Damián García Olmo, Prof MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>General Surgery Department (Hospital Universitario La Paz) and Cell Therapy laboratory</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Damián García Olmo, Prof MD</last_name>
    <phone>0034 912071022</phone>
    <email>damian.garcia@uam.es</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mariano A García Arranz, PhD</last_name>
    <phone>0034 912071022</phone>
    <email>mgarciaa.hulp@salud.madrid.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital Universitario La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano A García Arranz, PhD</last_name>
      <phone>0034 912071022</phone>
      <email>mgarciaa.hulp@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Damián García Olmo, Prof MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Héctor Guadalajara Labajo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tihomir G Hirstov, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <reference>
    <citation>Bey NM. A new technique in dealing with superior rectovaginal fistulae. J. Obstrt Gynecol 1934. 41: 579-587</citation>
  </reference>
  <reference>
    <citation>Given FT Jr. Rectovaginal fistula. A review of 20 years' experience in a community hospital. Am J Obstet Gynecol. 1970 Sep 1;108(1):41-6.</citation>
    <PMID>4916866</PMID>
  </reference>
  <reference>
    <citation>Daniels BT. Rectovaginal fistula: a clinical and pathological study. Doctoral dissertation. Minneapolis: University of Minnesota 1949</citation>
  </reference>
  <reference>
    <citation>LAIRD DR. Procedures used in treatment of complicated fistulas. Am J Surg. 1948 Dec;76(6):701-8.</citation>
    <PMID>18895064</PMID>
  </reference>
  <reference>
    <citation>Hoexter B, Labow SB, Moseson MD. Transanal rectovaginal fistula repair. Dis Colon Rectum. 1985 Aug;28(8):572-5.</citation>
    <PMID>4017820</PMID>
  </reference>
  <reference>
    <citation>Fry RD, Shemesh EI, Kodner IJ, Timmcke A. Techniques and results in the management of anal and perianal Crohn's disease. Surg Gynecol Obstet. 1989 Jan;168(1):42-8.</citation>
    <PMID>2909131</PMID>
  </reference>
  <reference>
    <citation>Radcliff AG, Ritchie JK, Hawley PR et al. Anal and rectovaginal fistulas in Crohn´s disease. Dis Colon Rectum. 1988; 31:91-94</citation>
  </reference>
  <reference>
    <citation>Tuxen PA, Castro AF. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum. 1979 Jan-Feb;22(1):58-62.</citation>
    <PMID>421652</PMID>
  </reference>
  <reference>
    <citation>Hellers G, Bergstrand O, Ewerth S, Holmström B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980 Jun;21(6):525-7.</citation>
    <PMID>7429313</PMID>
  </reference>
  <reference>
    <citation>Bandy LC, Addison A, Parker RT. Surgical management of rectovaginal fistulas in Crohn's disease. Am J Obstet Gynecol. 1983 Oct 15;147(4):359-63.</citation>
    <PMID>6624806</PMID>
  </reference>
  <reference>
    <citation>Bauer JJ, Sher ME, Jaffin H, Present D, Gelerent I. Transvaginal approach for repair of rectovaginal fistulae complicating Crohn's disease. Ann Surg. 1991 Feb;213(2):151-8.</citation>
    <PMID>1992942</PMID>
  </reference>
  <reference>
    <citation>Tsang CB, Madoff RD, Wong WD, Rothenberger DA, Finne CO, Singer D, Lowry AC. Anal sphincter integrity and function influences outcome in rectovaginal fistula repair. Dis Colon Rectum. 1998 Sep;41(9):1141-6. Review.</citation>
    <PMID>9749498</PMID>
  </reference>
  <reference>
    <citation>Andreani SM, Dang HH, Grondona P, Khan AZ, Edwards DP. Rectovaginal fistula in Crohn's disease. Dis Colon Rectum. 2007 Dec;50(12):2215-22. Epub 2007 Sep 11. Review.</citation>
    <PMID>17846837</PMID>
  </reference>
  <reference>
    <citation>García Olmo D, García-Verdugo JM, Alemany J, Gonzalez M, Gutierrez-Fuentes JA. CELL THERAPHY . Ed. Mac Graw Hill. Madrid 2007</citation>
  </reference>
  <reference>
    <citation>Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005 Feb 15;105(4):1815-22. Epub 2004 Oct 19.</citation>
    <PMID>15494428</PMID>
  </reference>
  <reference>
    <citation>Puissant B, Barreau C, Bourin P, Clavel C, Corre J, Bousquet C, Taureau C, Cousin B, Abbal M, Laharrague P, Penicaud L, Casteilla L, Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br J Haematol. 2005 Apr;129(1):118-29.</citation>
    <PMID>15801964</PMID>
  </reference>
  <reference>
    <citation>Tse WT, Pendleton JD, Beyer WM, Egalka MC, Guinan EC. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation. 2003 Feb 15;75(3):389-97.</citation>
    <PMID>12589164</PMID>
  </reference>
  <reference>
    <citation>Chamberlain G, Fox J, Ashton B, Middleton J. Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells. 2007 Nov;25(11):2739-49. Epub 2007 Jul 26. Review.</citation>
    <PMID>17656645</PMID>
  </reference>
  <reference>
    <citation>Le Blanc K, Ringdén O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2005 May;11(5):321-34. Review.</citation>
    <PMID>15846285</PMID>
  </reference>
  <reference>
    <citation>Maccario R, Podestà M, Moretta A, Cometa A, Comoli P, Montagna D, Daudt L, Ibatici A, Piaggio G, Pozzi S, Frassoni F, Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica. 2005 Apr;90(4):516-25.</citation>
    <PMID>15820948</PMID>
  </reference>
  <reference>
    <citation>Barrett AJ, Rezvani K, Solomon S, Dickinson AM, Wang XN, Stark G, Cullup H, Jarvis M, Middleton PG, Chao N. New developments in allotransplant immunology. Hematology Am Soc Hematol Educ Program. 2003:350-71. Review.</citation>
    <PMID>14633790</PMID>
  </reference>
  <reference>
    <citation>García-Olmo D, García-Arranz M, García LG, Cuellar ES, Blanco IF, Prianes LA, Montes JA, Pinto FL, Marcos DH, García-Sancho L. Autologous stem cell transplantation for treatment of rectovaginal fistula in perianal Crohn's disease: a new cell-based therapy. Int J Colorectal Dis. 2003 Sep;18(5):451-4. Epub 2003 May 20.</citation>
    <PMID>12756590</PMID>
  </reference>
  <reference>
    <citation>García-Olmo D, García-Arranz M, Herreros D, Pascual I, Peiro C, Rodríguez-Montes JA. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum. 2005 Jul;48(7):1416-23.</citation>
    <PMID>15933795</PMID>
  </reference>
  <reference>
    <citation>Garcia-Olmo D, Herreros D, Pascual I, Pascual JA, Del-Valle E, Zorrilla J, De-La-Quintana P, Garcia-Arranz M, Pascual M. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum. 2009 Jan;52(1):79-86. doi: 10.1007/DCR.0b013e3181973487.</citation>
    <PMID>19273960</PMID>
  </reference>
  <verification_date>April 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2012</study_first_submitted>
  <study_first_submitted_qc>April 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 27, 2012</study_first_posted>
  <last_update_submitted>April 25, 2012</last_update_submitted>
  <last_update_submitted_qc>April 25, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extremely complex perianal fistula</keyword>
  <keyword>Adipose Derived Stem Cells</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fistula</mesh_term>
    <mesh_term>Rectal Fistula</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

